This is a pilot study of the feasibility and safety of dapagliflozin (in addition to standard
of care treatment) for the treatment of pediatric patients with recurrent brain tumors. The
primary hypothesis is that dapagliflozin is well-tolerated and safe to use in this patient
population. The investigators also hypothesize that dapagliflozin will be efficacious as an
adjunct to front-line chemotherapy assessed by decreased tumor markers mediated by its
pleiotropic metabolic effects.